Gap Junction Modulation for Outer Blood-Retina Barrier Stability in AMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD), particularly dry AMD, are inadequate in preventing the progression to advanced geographic atrophy or neovascular AMD, and there is a need for effective therapies that maintain the integrity of the outer blood-retina barrier (oBRB) to prevent vision loss.
Innovation Solution
The use of Gap Junction-dependent cellular modulators, such as danegaptide, to stabilize cell-cell coupling and inhibit pathological hemichannel opening, thereby maintaining the integrity of the outer blood-retina barrier (oBRB) and preventing the progression of AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for AMD are used, then existing therapy options are maintained, but the treatments are inadequate in preventing progression to advanced geographic atrophy or neovascular AMD
Solution Approach 1:
The patent introduces gap junction modulators as intermediary substances that mediate between existing treatment limitations and the desired therapeutic outcome. These modulators target the specific molecular mechanism (gap junction channels) to prevent RPE cell death and barrier dysfunction, thereby bridging the gap between current inadequate therapies and effective prevention of advanced AMD stages.
Solution Approach 2:
The invention changes the therapeutic parameter from general AMD treatment to specific modulation of gap junction channel activity. By targeting connexin proteins and regulating intercellular communication parameters, the treatment adapts to prevent the specific pathological progression to geographic atrophy and neovascular AMD that current therapies cannot prevent.
2Stability of the object's composition
If gap junction modulators are used to stabilize cell-cell coupling, then integrity of the outer blood-retina barrier is maintained, but this requires novel therapeutic mechanisms beyond current treatments
Solution Approach 1:
The patent extracts and isolates the specific mechanism of gap junction channel dysfunction from the complex AMD pathology. By focusing on and targeting only the gap junction component (connexin proteins) rather than attempting to treat all aspects of AMD simultaneously, the therapy simplifies the approach while effectively maintaining outer blood-retina barrier integrity through stabilized cell-cell coupling.
3Object-generated harmful factors
If gap junction modulators inhibit pathological hemichannel opening, then vascular leakage is reduced, but this requires specific molecular targeting
Solution Approach 1:
Gap junction modulators serve as intermediary molecules that specifically bind to and regulate connexin proteins. These intermediaries reduce vascular leakage by preventing pathological hemichannel opening while maintaining normal gap junction function, thereby addressing the harmful effect with targeted molecular intervention that can be detected through gap junction channel activity assays.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The use of Gap Junction-dependent cellular modulators in the treatment or prevention of age-related macular degeneration (AMD) is disclosed, and more particularly to their use for the treatment or prevention of dry AMD (d-AMD) and to prevent progression to wet or neovascular or advanced angiogenic AMD or geographic atrophy (GA).